CD274 and non-small cell lung carcinoma: Nivolumab has demonstrated efficacy in the treatment of squamous cell lung cancer and Hodgkin's lymphoma, while MPDL-3280A, an anti-PD-L1 mAb, is effective in the treatment of bladder cancer and NSCLC 34.